Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $40.00 at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM) had its price target lifted by Stifel Nicolaus from $37.00 to $40.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the medical device company’s stock.

TNDM has been the topic of a number of other research reports. Citigroup raised their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a report on Wednesday, April 3rd. StockNews.com upgraded Tandem Diabetes Care from a sell rating to a hold rating in a report on Friday, April 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $37.27.

Tandem Diabetes Care Stock Up 10.2 %

Shares of Tandem Diabetes Care stock opened at $34.97 on Tuesday. Tandem Diabetes Care has a one year low of $13.82 and a one year high of $40.74. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The stock’s 50-day moving average is $30.30 and its 200 day moving average is $25.11. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -10.17 and a beta of 1.11.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. Equities research analysts anticipate that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Trading of Tandem Diabetes Care

A number of large investors have recently bought and sold shares of TNDM. RiverPark Advisors LLC purchased a new stake in Tandem Diabetes Care in the fourth quarter worth $27,000. MCF Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 79.3% in the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after acquiring an additional 445 shares during the period. Signaturefd LLC boosted its holdings in shares of Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after acquiring an additional 1,517 shares during the period. Arcadia Investment Management Corp MI boosted its holdings in shares of Tandem Diabetes Care by 141.6% in the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock worth $66,000 after acquiring an additional 1,085 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Tandem Diabetes Care by 51.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after acquiring an additional 1,099 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.